Loading clinical trials...
Loading clinical trials...
A Pilot Study of Daratumumab (CD38 Antagonist) in Patients with Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer
Conditions
Interventions
Biopsy
Daratumumab
+3 more
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
May 29, 2018
Primary Completion Date
January 27, 2025
Completion Date
January 27, 2025
Last Updated
January 30, 2025
NCT06863311
NCT07123090
NCT05987241
NCT07061964
NCT06349642
NCT07300241
Lead Sponsor
M.D. Anderson Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions